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Abstract
Arthritis pain affects millions of people worldwide yet we still have
only a limited understanding of what makes our joints ache. This
review examines the sensory innervation of diarthroidal joints and
discusses the neurophysiological processes that lead to the
generation of painful sensation. During inflammation, joint nerves
become sensitized to mechanical stimuli through the actions of
neuropeptides, eicosanoids, proteinase-activated receptors and
ion channel ligands. The contribution of immunocytes to arthritis
pain is also reviewed. Finally, the existence of an endogenous
analgesic system in joints is considered and the reasons for its
inability to control pain are postulated.
Introduction
According to a recent report released by the World Health
Organization [1], musculoskeletal disorders are the most
frequent cause of disability in the modern world, and the
prevalence of these diseases is rising at an alarming rate. The
most prominent reason for loss of joint mobility and function
is chronic or episodic pain, which leads to psychological
distress and impaired quality of life. Current therapies to help
alleviate joint pain have limited effectiveness and certain
drugs produce unwanted negative side effects, thereby
precluding their long-term use. In short, millions of patients
are suffering from the debilitating effects of joint pain for
which there is no satisfactory treatment. One of the reasons
for this lack of effective pain management is the paucity in our
knowledge of what actually causes joint pain. We are only
now starting to identify some of the mediators and
mechanisms that cause joints to become painful, allowing us
to develop future new targets that could better alleviate
arthritis pain. This review summarizes what is known about
the origin of joint pain by describing the neurobiological
processes initiated in the joint that give rise to neural signals
and that are ultimately decoded by the central nervous
system into pain perception.
Joint innervation and nociception
Knee joints are richly innervated by sensory and sympathetic
nerves [2,3]. Postganglionic sympathetic fibres terminate
near articular blood vessels, where they regulate joint blood
flow through varying degrees of vasoconstrictor tone. The
primary function of sensory nerves is to detect and transmit
mechanical information from the joint to the central nervous
system. Large diameter myelinated nerve fibres encode and
transmit proprioceptive signals, which can be interpreted as
being either dynamic (movement sensations) or static
(position sense). Pain-sensing nerve fibres are typically less
than 5 µm in diameter and are either unmyelinated (type IV) or
myelinated with an unmyelinated ‘free’ nerve ending (type III).
These slowly conducting fibres typically have a high threshold
and only respond to noxious mechanical stimuli, and as such
are referred to as nociceptors [4]. In the rat and cat, 80% of
all knee joint afferent nerve fibres are nociceptive [5-7],
suggesting that joints are astutely designed to sense
abnormal and potentially destructive movement.
Nociceptors are located throughout the joint, having been
identified in the capsule, ligaments, menisci, periosteum and
subchondral bone [8-13]. The most distal segment of type III
and type IV afferents is devoid of a myelin sheath and
perineurium, and it is believed that this is the sensory region
of the nociceptive nerve. Transmission electron microscopy
revealed an hour glass shape repeating pattern along the
length of type III and type IV nerve terminals, and the multiple
bulbous areas exhibit the characteristic features of receptive
sites [14]. It is within these ‘bead-like’ structures on the
terminals of ‘free’ nerve endings that joint pain originates.
The question of how a painful mechanical stimulus is
converted into an electrical signal that can then be
propagated along sensory nerves to the central nervous
system is still unclear. The exposed nature of sensory ‘free’
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nerve endings means that the axolemma of these fibres is
probably subjected to significant stretch during joint move-
ment. The recent identification of mechanogated ion channels
on type III and type IV knee joint afferents by electrophysio-
logical means provided the first insight into the physiological
mechanisms responsible for mechanotransduction in joints
[15]. The present theory is that movement of the joint
generates shear stresses on the axolemma of the ‘free’ nerve
endings, resulting in the opening of mechanogated ion
channels. This leads to a depolarization of the nerve terminal
and the generation of action potentials, which are subse-
quently transmitted to the central nervous system where they
are decoded into mechanosensation. If a noxious movement
is applied to the joint, the firing rate of the afferent nerve
increases dramatically and the central nervous system
interprets this nociceptive activity as pain [16-18].
Peripheral sensitization and joint inflammation
During inflammation, major plasticity changes occur in the
peripheral and central nervous systems that lower the pain
thresholds, giving rise to allodynia (pain in response to a
normally innocuous stimulus) and hyperalgesia (heightened
pain intensity in response to a normally painful stimulus).
One means by which pain is generated in arthritic joints is
via the stimulation of so-called ‘silent nociceptors’. These
afferent nerve fibres are quiescent in normal joints; however,
following tissue injury or induction of inflammation these
nociceptors become active and start to send nociceptive
information to the central nervous system [18-20]. This
supplementary input from the periphery by the ‘silent
nociceptors’ is one of the contributing factors responsible
for the generation of arthritis pain.
An additional process that initiates arthritis pain is peripheral
sensitization wherein the activation threshold of joint
nociceptors is reduced and afferent nerves become hyper-
responsive to both normal and noxious types of movement
[18-21]. The pioneering work of Coggeshall and coworkers
[21] as well as Schaible and Schmidt [19,20,22] showed
that chemical induction of an acute synovitis by intra-articular
injection of kaolin and carrageenan reduced the activation
threshold of type III and type IV knee joint afferents. The
firing frequency of these mechanosensory nerves was
dramatically enhanced during normal joint movements as
well as during hyperextension and hyperflexion of the knee. It
is believed that this augmentation in neuronal firing rate is
interpreted by the central nervous system as joint pain and
that this process is the neurophysiological basis for joint
allodynia and hyperalgesia in these acutely inflamed joints.
Decreased mechanical threshold and heightened afferent
discharge rate have also been noted in adjuvant-induced
chronic arthritis [23,24] as well as in an animal model of
osteoarthritis [25]. Resting neuronal activity in the absence
of any mechanical stimulation was also described in these
arthritis models, which is consistent with an awakening of
‘silent nociceptors’. This spontaneous firing of joint sensory
nerves accounts for the resting joint pain commonly
described by arthritis patients.
Factors contributing to joint peripheral
sensitization
The evidence presented thus far clearly indicates that
peripheral sensitization of joint afferents is the origin of
arthritis pain. Hence, a greater understanding of the
mechanisms and mediators responsible for the generation
and maintenance of joint sensitization could lead to
development of novel drug targets that could alleviate or even
abolish arthritis pain. The factors that alter joint
mechanosensitivity and promote nociception can be divided
into two separate groups: mechanical factors and
inflammatory mediators.
Mechanical factors involved in joint nociception
Diarthroidal joints are enveloped by a fibrous capsule that
contains synovial fluid, the volume of which in normal human
knee joints is between 1 and 4 ml. Following joint injury or
during inflammation, synovial blood vessels become
increasingly permeable to plasma proteins, which can leak
out of the vasculature and accumulate in the intra-articular
space. The subsequent shift in Starling forces promotes fluid
exudation into the joint with subsequent oedema formation.
Because the joint is an enclosed space, this effusion causes
a dramatic increase in intra-articular pressure. In normal
joints, intra-articular pressure is subatmospheric, ranging from
–2 to –10 mmHg [26,27]; however, in rheumatoid arthritic
knees synovial fluid volume can rise to 60 ml or more, with a
concomitant increase in intra-articular pressure to
approximately 20 mmHg supra-atmospheric [28]. A study in
which a solution of dextrose and saline was infused into the
knee joint revealed that intra-articular pressure rose more
steeply in arthritic patients than in normal control individuals
[28], probably due to a loss of capsular viscoelasticity and
the occurrence of an invading pannus. As intra-articular
pressure increased, the participants reported greater tight-
ness around their knee and ultimately moderate pain was
experienced. Animal studies [29,30] have shown that an
elevation in intra-articular pressure results in burst firing of
articular afferents, and the frequency of these neuronal
discharges correlates with the level of pressure incurred.
Thus, the increased intra-articular pressure associated with
oedema formation in arthritic joints likely activates joint
nociceptors, leading to pain.
Acute trauma and repetitive stress injuries are major causes
of joint pain and disability. Acute joint trauma, such as sport-
related injuries, typically involves damage to multiple soft
tissues in the joint with varying degrees of damage. A large
body of research has found that rupture of articular ligaments
leads to joint instability and consequently abnormal loading
patterns in the joint [31-34]. The relatively poor healing
capacity of joint ligaments means that, over time, chronic
instability results in focal erosion of the articulating surfaces,Page 3 of 10
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ultimately leading to joint degeneration and possibly
osteoarthritis [35-40]. Inflammatory mediators released into
the joint following trauma as well as the accumulation of
cartilage degeneration products over time are probably the
major contributors to peripheral sensitization in acute and
repetitive joint injury, although the identity of these chemical
agents is currently unknown. Altered joint biomechanics is
also a likely candidate for initiating and maintaining joint pain;
however, the processes that link loss of joint function and
nociception have never been fully investigated. In one of the
few reports on this matter, transection of the anterior
cruciate ligament was found to cause increased electrical
activity in the medial and posterior articular nerves in
response to passive movement of the knee [41]. Again, it is
unclear whether this heightened mechanosensitivity is due to
local release of chemical sensitizers into the joint following
surgery or whether abnormally high forces now act on the
remaining uninjured articular tissues, leading to a rise in
afferent firing rate. It is entirely feasible that both mechanical
and chemical processes occur simultaneously in these
unstable joints to generate pain, but further research is
required to test this hypothesis.
Inflammatory mediators and peripheral sensitization
Following injury or pathogenic infection, joints typically exhibit
a natural inflammatory response that mainly affects the
synovium (synovitis). This process is necessary for the innate
repair of damaged tissues, allowing the joint to recoup normal
function. Inflammatory mediators released into the joint from
such sources as nerves, immunocytes, synoviocytes, and
vascular endothelium help to orchestrate these healing
responses. These same inflammatory mediators also act on
joint sensory nerves, leading to either excitation or
sensitization. Indeed, local application of various compounds
to normal joints elicits a frequency and burst profile of joint
afferents that is similar to recordings made in arthritic knees.
Identification of the inflammatory agents that evoke
nociception is currently underway, and results from these
studies will be of major therapeutic value in revealing novel
targets that could inhibit peripheral sensitization and hence
pain. The following is an overview of some of the better
characterized inflammatory mediators that are associated
with joint nociception.
Neuropeptides
Neuropeptides are a family of chemical mediators that are
stored and released from the terminals of autonomic nerves
and slowly conducting joint afferents. Local axon reflexes are
responsible for the peripheral release of neuropeptides from
sensory nerves, leading to neurogenic inflammation.
The inflammatory neuropeptides substance P (SP), calcitonin
gene-related peptide (CGRP), and vasoactive intestinal
peptide (VIP) have all been immunolocalized in joint tissues
and their levels increase during arthritis [13,42-46]. Electro-
physiological recording from knee joint primary afferents
found that although local administration of SP had no direct
effect on neuronal firing properties, it did cause peripheral
sensitization of the nerves in response to normal and noxious
joint movements [47]. Ionophoretic application of CGRP
close to spinal cord neurones that have an input from knee
joint afferents caused an increase in firing rate of these spinal,
wide dynamic range neurones [48]. Furthermore, the hyper-
responsiveness of these neurones following acute synovitis
could be blocked by the selective antagonist CGRP8-37 [48],
indicating that CGRP plays an important role in the central
neurotransmission of painful mechanosensory information
arising from the knee. The ability of CGRP to alter joint
afferent activity peripherally has not yet been demonstrated.
VIP is a 28-amino-acid neuropeptide that is contained in
postganglionic sympathetic as well as capsaicin-sensitive
sensory nerve fibres innervating the joint capsule [49-51].
Treatment of rat knee joints with exogenous VIP results in
mechanonociceptive responses, as demonstrated by
enhanced afferent firing frequency during joint rotation [25].
Animal behavioural studies confirmed that this elevation in
sensory input to the central nervous system would translate
into a pain response, because intra-articular injection of VIP
causes a negative shift in hindlimb weight bearing as well as
a reduction in hindpaw reaction thresholds to a tactile
mechanical stimulus [52]. Interestingly, treatment of
osteoarthritic knees with the VIP antagonist VIP6-28 reduced
nociceptive and pain levels in these animals, highlighting the
potential benefits in using this neuropeptide blocker to
control arthritis pain [25,52].
A further sensory neuropeptide called nociceptin/orphanin
FQ (N/OFQ) is also known to alter joint mechanosensitivity
and modulate arthritis pain. N/OFQ is an opioid-like
neuropeptide that has been immunolocalized in the peripheral
and central nervous systems [53-55], where it controls
central pain mechanisms [56-58]. In the knee joint, N/OFQ
was found to have a dual effect on sensory nerve activity
depending on dose of peptide, on level of mechanical
manipulation of the knee, and on whether the joint was
inflamed [59]. With normal rotation of control and acutely
inflamed rat knees, N/OFQ had a sensitizing effect on joint
afferents; however, high doses of N/OFQ desensitized joint
mechanosensory nerves during hyper-rotation of inflamed
knees. It was later found that the sensitizing effect of N/OFQ
was due to the secondary release of SP into the joint
because the selective NK1 receptor antagonist RP67580
blocked N/OFQ-mediated nociception [60]. The ability of
N/OFQ to induce hyperalgesia and allodynia in the joint was
recently demonstrated in experiments in which peripheral
injection of N/OFQ produced a deficit in ipsilateral hindlimb
weight bearing and increased von Frey hair mechano-
sensitivity [61].
Taken together, these studies clearly show that the sensory
neuropeptides SP, CGRP, VIP and N/OFQ are all involved in
the generation and promotion of knee pain.
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Eicosanoids are lipid membrane derived metabolites of
arachidonic acid that include the prostaglandins, leukotrienes,
lipoxins, thromboxanes and endocannabinoids. The most
heavily studied eicosanoids with respect to joint inflammation
and pain are the prostaglandins, which are extensively
reviewed elsewhere [62-64]. Prostaglandins are formed via a
complex enzymatic pathway in which arachidonic acid
released from membrane phospholipids is oxygenated by
cyclo-oxygenases to produce cyclic endoperoxide prosta-
glandins. Tissue specific synthases and isomerases then
transform these chemically unstable intermediates into the
prostaglandins, thromboxanes and prostacyclins.
The pain field has generally focused on the activity of the
cyclo-oxygenases, of which there are two isoforms: cyclo-
oxygenase (COX)-1 and COX-2 (for review, see Smith and
coworkers [65]). COX-1 is constitutively expressed in most
cells, where its function is to maintain normal physiological
processes in the tissue such as blood flow. Conversely,
COX-2 is primarily upregulated during inflammatory situations
by various inflammatory mediators such as cytokines [66],
and it is therefore often referred to as the inducible isoform of
the enzyme (although COX-2 is constitutively expressed in
the central nervous system and kidney). In joints, COX-2 is
not normally expressed but has been found to occur in
significant amounts in the synovium, macrophages and
endothelial cells of rheumatoid arthritis patients [67,68].
Because COX-2 is the predominant cyclo-oxygenase present
at the site of inflammation, drugs that selectively inhibit COX-2
activity (the coxibs) were believed to have better therapeutic
value than the nonselective nonsteroidal anti-inflammatory
drugs (NSAIDs). It was initially thought that another advan-
tage to coxib use was that it produced less gastrointestinal
toxicity compared with traditional NSAIDs [69]. Although the
anti-inflammatory and analgesic capacity of coxibs in arthritis
is convincing, a number of these agents produce severely
hazardous side effects such as myocardial infarction,
hypertension and chronic renal failure. Clearly, a peripherally
acting NSAID or intra-articular treatment with either selective
and/or nonselective prostaglandin inhibitors could prove to
be beneficial in treating joint pain while minimizing systemic
side effects.
Peripheral intra-arterial injection of prostacyclin (prosta-
glandin [PG]I2), PGE1 and PGE2 have all been found to
sensitize joint afferents in the rat and cat [70-72]. The
sensitizing effect of these prostanoids was rapid in onset and
led to an augmentation in afferent firing rate in response to
mechanical as well as chemical stimuli. Furthermore, the
sensitization of joint nociceptors by acute and chronic
inflammation can be inhibited by the nonselective NSAIDs
indomethacin and acetylsalicylic acid [73-75]. A recent study
demonstrated that systemic administration of the COX-2
inhibitor meloxicam reduced pain evoked vocalization and
joint favouring in adjuvant monoarthritic rats [76], although a
direct antinociceptive effect of the drug on joint nociceptors
was not definitively shown. Further study is necessary,
therefore, to test the effectiveness of highly selective coxibs
on joint nociception using animal models of arthritis.
The endocannabinoid anandamide is enzymatically
synthesized from free arachidonic acid and ethanolamine
[77]. Anandamide is a nonselective ligand that binds to both
CB1 and CB2 cannabinoid G-protein-coupled receptors. CB1
receptors are mainly found on central and peripheral nerves,
whereas CB2 receptors are associated with immunocytes
[78-82]. The location of neuronal central and peripheral CB
receptors indicates that activation of these receptors could
modulate pain generation and perception [78,82-85]. In
joints, high doses of anandamide actually caused excitation of
polymodal sensory nerves, indicating a pro-nociceptive effect
of the endocannabinoid [86], although the authors did
suggest that low doses of anandamide could elicit an anti-
nociceptive effect. An alternative explanation is the fact that
anandamide acts on both CB receptor subtypes, and the net
effect of the cannabinoid is an excitatory action. Experiments
are currently underway to test the role of selective CB1 and
CB2 agonists on joint mechanosensitivity to determine
whether a differential response exists between these two
receptor subtypes. An interesting aspect of the anandamide
study was that its stimulatory effect on joint nociceptors was
attained by activating the transient receptor potential (TRP)
vanilloid channel 1 (TRPV1). This pathway was reaffirmed by
joint blood flow experiments that showed that the vasomotor
effects of a selective CB1 agonist in rat knees could be
blocked by TRPV1 antagonism [87]. Zygmunt and coworkers
[88] deduced that anandamide activation of TRPV1 channels
on sensory nerves causes the secondary release of CGRP. It
is possible, therefore, that the excitatory action of
anandamide on joint afferents could be due to the secondary
release of CGRP or other inflammatory neuropeptides into
the joint.
Ion channel ligands
Multiple different types of ion channels exist on the terminals
of nociceptors, and their activation either directly or via
receptor coupling is necessary for nociceptive processing to
occur. Opening of voltage-gated sodium channels permits
depolarization of the afferent nerve terminal and propagation
of action potentials towards the central nervous system.
Sodium channels are typically blocked by the puffer fish
poison tetrodotoxin (TTX); however, a significant population
of sodium channels present on small diameter sensory
neurones are resistant to TTX, and their function is to
modulate nociceptive neurotransmission [89,90]. Chronic
inflammation with concomitant persistence in nociceptive
input has been shown to upregulate sodium channel expres-
sion and sodium channel currents in various tissues [91,92],
including the temperomandibular joint [93]. Inflammatory
mediators such as PGE2, adenosine and 5-hydroxytryptamine
have all be shown to augment sodium channel kinetics and
Arthritis Research & Therapy    Vol 8 No 6 McDougall
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sodium channels on nociceptors may be a viable means of
inhibiting pain. Indeed, treatment of adjuvant monoarthritic rat
ankle joints with the sodium channel blockers mexilitine and
crobenetine inhibited joint mechanical hyperalgesia and
alleviated restrictions in animal mobility [96].
Calcium channels have also been implicated in pain
processing (for review, see Yaksh [97]). Opening of voltage-
gated calcium channels on primary afferent nerves leads to
an increase in intracellular calcium concentration and conse-
quently neurotransmitter release into the extraneuronal space.
As is described above, a large number of these neuro-
mediators can have a sensitizing effect on the sensory nerve
and thereby promote nociception. In addition to the
secondary release of algogenic agents from sensory nerve
terminals, activation of voltage-gated calcium channels can
directly have a positive effect on neuronal excitability and
hence firing rate [97]. The role of calcium channels in joint
pain is largely unexplored. In one of the few studies to
address this issue, the anticonvulsant gabapentin, which
binds to the α2δ subunit of calcium channels, was shown to
reduce the mechanosensitivity of normal and acutely inflamed
knee joints [98]. The full relevance of this finding to calcium
channel neurobiology is uncertain.
In addition to voltage-gated cation channels, knee joints were
recently found to possess mechanogated ion channels that
are sensitive to changes in shear stress forces being applied
to the neuronal membrane [15]. The forces generated by
physical movement of a joint are transmitted throughout the
organ where they are perceived by the articular innervation.
The shear stress causes a conformational change in the
mechanogated ion channels present on the nerve terminal,
which leads to channel opening and consequently nerve
depolarization. If movement becomes noxious, then greater
forces are applied to the joint and the probability of
mechanogated ion channel opening is increased and
depolarization events become more frequent [15]. This
enhanced activity is the molecular basis of joint pain.
Another superfamily of ion channels that has received a lot of
attention recently are the TRP channels. Of particular interest
in pain research are the TRPM (melanostatin) and the TRPV
(vanilloid) channel subfamilies. The eighth member of the
TRPM channels (TRPM8) is activated by cooling temper-
atures (22-26°C) as well as by agents such as menthol that
produce a cool sensation [99,100]. It is thought that
pharmacological activation of TRPM8 channels could elicit an
anti-nociceptive effect in much the same way that applying
ice packs to an injured joint can reduce pain sensation.
Current research into this channel, however, has been
hampered by the lack of efficacious and highly selective
pharmacological tools. The use of heat to help control joint
aches and pains has been appreciated for many years, but
the molecular mechanism by which this is achieved has only
recently been elucidated. The ion channel responsible for
noxious thermosensation is TRPV1, which was first identified
on rat sensory neurones by an expression-cloning approach
[101]. In addition to being activated by temperatures above
43°C, TRPV1 is sensitive to protons, lipids, phorbols and
cannabinoids. The CB1 agonist arachidonyl-2-chloroethyl-
amide, for example, exerts its physiological effects in joints via
a TRPV1-dependent pathway [87]. Unlike other TRP channels,
several agonists and antagonists have been developed that
are selective for TRPV1, including the blocker SB366791,
which has been shown to be effective in joint tissues [102].
Electrophysiological studies have revealed that capsaicin (the
hot spicy component of chilli peppers) sensitizes joint
afferents probably by causing secondary release of inflam-
matory neuropeptides into the joint (unpublished obser-
vations). The joint subsequently becomes insensitive to
further noxious mechanical stimuli, although the precise
mechanism underlying this process is unknown.
Other chemical mediators
The preceding discussion has addressed the most commonly
studied inflammatory mediators that are known to sensitize
joint afferents, but it is far from exhaustive. Other chemical
compounds that demonstrate peripheral sensitization in joints
include bradykinin [103,104], histamine [105], 5-hydroxy-
tryptamine [106], adenosine [107,108], and nitric oxide
[109]. As the list of new potential targets continues to grow
at a rapid rate, this exciting area of joint neurobiology will
probably yield useful and beneficial pain control medicines
that could act on one or a combination of these nociceptive
pathways.
Neuroimmune pain pathways
The histological identification of synovial mast cells in close
proximity to type III and type IV knee joint afferents [110,111],
as well as the ability of neuromediators to stimulate leucocyte
infiltration into joints [112,113] suggests an important
involvement of immunocytes in neurogenic inflammation and
pain. This concept is supported by the fact that mast cells
and neutrophils can be activated by various sensory neuro-
peptides [114-123], resulting in explosive degranulation and
subsequent release of inflammatory mediators into the local
microenvironment. These immunocyte-derived factors can
themselves cause joint inflammation and impart tissue
hyperalgesia. For example, in acutely inflamed knees the
vasomotor effect of N/OFQ is dependent on the presence of
synovial mast cells and leucocytes [124], indicating a
neuroimmune mode of action for this neuropeptide.
Another group of agents that recently have been found to
activate mast cells leading to pain and inflammation are the
serine proteinases. Proteinase levels are known to be
augmented in patients with inflammatory joint disease
[125-128], and it is believed that their enzymatic destruction
of cartilage and other intra-articular tissues is a major
contributing factor to the pathogenesis of rheumatoid
Available online http://arthritis-research.com/content/8/6/220
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proteinases were recently found to regulate cell signalling via
specialized G-protein-coupled receptors. The unique
characteristic of these proteinase-activated receptors (PARs)
is the novel mechanism by which these receptors are
triggered. Firstly, the proteinase hydrolyzes a specific arginine
cleavage site located on the extracellular amino-terminus of
the G-protein-coupled receptor, thereby exposing a new
amino-terminal sequence. This modified amino-terminal
sequence, while remaining tethered to the receptor, can now
bind to a docking domain within the same receptor, leading
to activation and cell signalling. Four PARs have thus far been
identified (PAR1 to PAR4), and evidence is emerging that
suggests that these receptors are involved in pain signalling
[129,130]. In knee joint electrophysiology studies we found
that administration of a PAR4-activating peptide can evoke
spontaneous activity and sensitize joint afferents in response
to mechanical manipulation of the knee (Figure 1). Inhibition
of proteinase activity in diseased joints could have the dual
benefit of reducing nociception as well as attenuating joint
destruction through proteolysis. Thus, the PARs are an
exciting new target for investigating joint pain modulation and
for the potential development of disease-modifying drugs.
Endogenous anti-nociceptive ligands
In an attempt to offset peripheral sensitization responses, it is
becoming evident that joints also possess anti-nociceptive
capabilities. The endogenous µ-opioid receptor ligand endo-
morphin-1 has been immunolocalized in capsaicin-sensitive
nerves innervating rat synovial tissue [131,132], where it acts
to reduce inflammation and inhibit nociception following an
acute synovitis [24]. Interestingly, the anti-nociceptive
capacity of endomorphin-1 was lost during chronic arthritis
due to a reduction in µ-opioid receptor expression in the joint.
This observation could begin to explain why the endogenous
opioid system is unable to ameliorate arthritis pain. Other
substances that are tonically released into the joint to offset
inflammation-induced peripheral sensitization include galanin
[133] and somatostatin [134]. These peptides have been
shown to reduce nociceptor activity during noxious
movement of normal knees as well as during normal rotation
and hyper-rotation of acutely inflamed joints. Future research
is required to characterize other endogenous anti-nociceptive
mediators and to elucidate the reasons for their limited
effectiveness in controlling arthritis pain.
Central processes in joint pain
Action potentials are transmitted along nociceptors from the
knee to the central nervous system and enter the dorsum of
the spinal cord predominantly in the lumbosacral region. Joint
nociceptors terminate in the dorsal horn of the spinal cord,
where they synapse with spinal neurones. These neurones
constitute either spinal inter-neurones that aim to modulate
sensory input, or ascending processes that transmit noci-
ceptive information to the brain via the spinothalamic, spino-
mesencephalic, spinoreticular and spinocervical tracts.
Neurophysiological processes at the intraspinal level can
either intensify (central sensitization) or dampen (inhibition)
the nociceptor signals before they reach the sensory cortex.
As such, the intensity of the nociceptive information
originating from joint primary afferents can undergo
significant modification before leaving the spinal cord. The
complex mechanisms and chemical mediators involved in
these central processes are outside the scope of this review.
An initial attempt to determine the regions of the brain to
which joint nerves project was recently reported in the rat. By
measuring evoked potentials in the cerebral cortex in
response to electrical stimulation the knee joint innervation, it
was determined that joint afferents project to areas SI and SII
of the somatosensory cortex [135]. By mechanisms that are
not clearly understood, the brain interprets these high-
intensity signals as joint pain. In addition to this cognitive
aspect of arthritis pain, there is also an affective or emotional
component to the disease. Patients who suffer from chronic
arthritis pain exhibit clinical signs of depression and anxiety
that appear to have a physiological basis [136]. In one of the
few studies to try to discern the neurophysiological pathways
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Figure 1
Specimen recording from a knee joint afferent fibre during rotation (torque) of the knee. Close intra-arterial injection of a PAR4 agonist caused
spontaneous nerve activity as well as increased afferent firing rate during normal rotation compared with control. This PAR4 sensitization of the
nerve would be decoded as joint pain by the central nervous system. PAR, proteinase-activated receptor.responsible for the negative affect of arthritis pain,
Neugebauer and Li [137] recorded from neurones located in
the amygdala, an area of the brain that is synonymous with
pain and emotion [138]. They found that noxious mechanical
stimuli applied to acutely inflamed joints had an excitatory
effect on the firing rate of neurones in the central nucleus of
the amygdala. These data provide the first electro-
physiological evidence that the amygdala is involved in
transforming nociceptive information arising from arthritic
joints into an emotional, painful experience.
Conclusion
Recent advances in molecular technology and the develop-
ment of selective and efficacious pharmacological tools have
enabled us to piece together the complex processes involved
in the generation of arthritis pain. Nevertheless, as this review
consistently reminds us, there are still very large gaps in our
knowledge of what is occurring in the nociceptors to maintain
this chronic pain state. For example, why is some arthritis pain
episodic whereas other patients complain of chronic
persistent joint pain? Why is there a disconnect between the
degree of joint deterioration and the level of joint pain
reported? As we get older, our peripheral nerves degenerate
and as such some patients may be experiencing neuropathic
pain rather than arthritis pain per se. Indeed, gabapentin (a
drug commonly prescribed to relieve neuropathic pain)
shows some promise in controlling arthritis pain [98].
Although analgesia could be achieved by intervening at
different levels in the pain pathway, the possibility of reducing
pain in the periphery is very appealing because drug doses
can be titred to a lower level and there is less scope for
negative systemic side effects. The fact that pain and
inflammation are inherently linked indicates that interventions
that relieve the symptoms of arthritis may also moderate the
severity of the underlying disease. Carefully planned studies
using multiple arthritis models and relevant methodological
approaches are therefore imperative to further our
understanding of the origin of joint pain.
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